First Ascent Biomedical in the News
First Ascent Biomedical in the News
First Ascent Biomedical Inc., a clinical-stage functional precision medicine company advancing the novel xDRIVE (Ex [...]
Inside Precision Medicine April 18, 2024 IPM interviewed Dr. Diana Azzam First Ascent co-founder and [...]
Groundbreaking findings published in Nature Medicine shows improved outcomes when standard treatments fail Miami, [...]
Function Precision Medicine (FPM) and AI to provide new treatment options for minority childhood cancer [...]
Risk or presence of metastasis in medulloblastoma causes substantial treatment-related morbidity and overall mortality. Read [...]
Systemic therapy for metastatic clear cell sarcoma (CCS) bearing EWSR1-CREB1/ATF1 fusions remains an unmet clinical [...]
Over the past 25 years, chemotherapy regimens for osteosarcoma have failed to improve the 65-70% [...]
Metastatic epithelioid sarcoma (EPS) remains a largely unmet clinical need in children, adolescents and young [...]
The collaboration between Lucem Health, Mayo Clinic Platform, and First Ascent Biomedical will reduce complexity [...]
Moving drugs to and through phased trials, especially in cancer, is daunting and riddled with [...]
orrectly diagnosing a rare childhood cancer such as sarcoma can be critical to assigning the [...]
Correctly diagnosing a rare childhood cancer such as sarcoma can be critical to assigning the [...]
Preclinical cancer research ranges from in vitro studies that are inexpensive and not necessarily reflective [...]
Wilms tumor is the most common childhood kidney cancer. Two distinct histological subtypes of Wilms [...]
As high-throughput sequencing experiments become more widely used in pre-clinical and clinical settings, pharmacogenetic and [...]
Diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain tumor, afflicts approximately 350 new patients [...]
Specific mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia type 2A, a [...]
Diffuse intrinsic pontine glioma (DIPG) is a devastating pediatric cancer with unmet clinical need. DIPG [...]
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood with a propensity to metastasize. [...]
Rhabdomyosarcoma (RMS) is a mesenchymal malignancy phenocopying muscle and is among the leading causes of [...]
Rhabdomyosarcoma (RMS) is a mesenchymal malignancy phenocopying muscle and is among the leading causes of [...]
In this case report we evaluate the genetics of and scientific basis of therapeutic options [...]
Nonrhabdomyosarcoma soft-tissue sarcomas (STSs) are a class of 50+ cancers arising in muscle and soft [...]
Rhabdomyosarcoma (RMS) is the most common childhood soft-tissue sarcoma. The largest subtype of RMS is [...]
CIC-rearranged sarcomas (CRSs) have recently been characterized as a distinct sarcoma subgroup with a less [...]
Relapsed and metastatic hepatoblastoma represents an unmet clinical need with limited chemotherapy treatment options. Read [...]
Cancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine [...]
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. [...]
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival [...]
Feline injection-site sarcoma (FISS), an aggressive iatrogenic subcutaneous malignancy, is challenging to manage clinically and [...]
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an unmet clinical [...]
Diffuse intrinsic pontine glioma (DIPG) is a universally fatal childhood cancer of the brain. Despite [...]
In complex, highly unstable genomes such as in osteosarcoma, targeting aberrant checkpoint processes (metabolic, cell [...]
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic [...]
Design of personalized targeted therapies involve modeling of patient sensitivity to various drugs and drug [...]
The prediction of tumor sensitivity to targeted drugs remains a major challenge in the design [...]
Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood cancer. We performed a chemical screen [...]
Diffuse intrinsic pontine gliomas (DIPGs) represent a particularly lethal type of pediatric brain cancer with [...]
A framework for design of personalized cancer therapy requires the ability to predict the sensitivity [...]
Drugs that target specific proteins are a major paradigm in cancer research. In this article, [...]
Alveolar rhabdomyosarcoma (aRMS) is a myogenic childhood sarcoma frequently associated with a translocation-mediated fusion gene, [...]
The success of targeted anti-cancer drugs are frequently hindered by the lack of knowledge of [...]
Drugs targeting specific kinases are becoming common in cancer research and are a basis for [...]
Genetic Regulatory Networks (GRNs) are frequently modeled as Markov Chains providing the transition probabilities of [...]
Publication and Pharma Partners
